$ACUR
ACURA PHARMACEUTICALS, INC Stock $acur

$acur Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000114420414064695 Filed on November 03, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q4
Revenue	$529.0K	$145.0K	$35.00K
YoY Change	1411.43%	74.7%
Cost Of Revenue	$40.00K	$110.0K	$40.00K
YoY Change	0.0%	37.5%
Gross Profit	$490.0K	$40.00K	$0.00
YoY Change		300.0%
Gross Profit Margin	92.63%	27.59%	0.0%
Selling, General & Admin	$2.040M	$1.728M	$2.790M
YoY Change	-26.88%	-10.97%	50.81%
% of Gross Profit	416.33%	4320.0%
Research & Development	$910.0K	$955.0K	$800.0K
YoY Change	13.75%	-25.91%	-33.88%
% of Gross Profit	185.71%	2387.5%
Depreciation & Amortization	$190.0K	$30.00K	$30.00K
YoY Change	533.33%	0.0%	0.0%
% of Gross Profit	38.78%	75.0%
Operating Expenses	$2.984M	$2.791M	$3.516M
YoY Change	-15.13%	-15.63%	15.01%
Operating Profit	-$2.455M	-$2.646M	-$3.481M
YoY Change	-29.47%	-17.95%	13.87%
Interest Expense	-$240.0K	$304.0K	$60.00K
YoY Change	-500.0%		-25.0%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$258.0K
YoY Change		-837.14%
Pretax Income	-$2.700M	-$2.904M	-$3.420M
YoY Change	-21.05%	-8.97%	13.25%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.696M	-$2.904M	-$3.417M
YoY Change	-21.1%	-8.97%	13.3%
Net Earnings / Revenue	-509.64%	-2002.76%	-9762.86%
Basic Earnings Per Share	-$0.30	-$0.30	-$0.07
Diluted Earnings Per Share	-$0.30	-$0.30	-$0.07
COMMON SHARES
Basic Shares Outstanding	48.85M shares	48.92K shares	48.32M shares
Diluted Shares Outstanding		48.92K shares

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.10M	$14.56M	$26.07M
YoY Change	-53.61%	-25.05%	-4.92%
Cash & Equivalents	$774.0K	$1.250M	$12.34M
Short-Term Investments	$11.32M	$13.31M	$13.73M
Other Short-Term Assets	$690.0K	$950.0K	$820.0K
YoY Change	-15.85%	10.47%	203.7%
Inventory	$304.0K	$403.0K	$251.0K
Prepaid Expenses
Receivables	$80.00K	$130.0K	$190.0K
Other Receivables	$60.00K	$90.00K	$120.0K
Total Short-Term Assets	$13.23M	$16.14M	$27.45M
YoY Change	-51.8%	-22.28%	-1.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$957.0K	$960.0K	$941.0K
YoY Change	1.7%	-1.23%	-10.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$180.0K	$240.0K
YoY Change	-100.0%	800.0%	2300.0%
Total Long-Term Assets	$2.802M	$3.140M	$1.177M
YoY Change	138.06%	215.26%	10.21%
TOTAL ASSETS
Total Short-Term Assets	$13.23M	$16.14M	$27.45M
Total Long-Term Assets	$2.802M	$3.140M	$1.177M
Total Assets	$16.03M	$19.28M	$28.63M
YoY Change	-44.0%	-11.41%	-1.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$217.0K	$116.0K	$274.0K
YoY Change	-20.8%	-54.15%	-72.43%
Accrued Expenses	$568.0K	$1.488M	$541.0K
YoY Change	4.99%	92.0%	30.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.758M	$1.160M	$0.00
YoY Change
Total Short-Term Liabilities	$2.992M	$3.032M	$1.107M
YoY Change	170.28%	172.91%	-22.26%
LONG-TERM LIABILITIES
Long-Term Debt	$7.799M	$8.530M	$9.600M
YoY Change	-18.76%
Other Long-Term Liabilities	$190.0K	$140.0K	$0.00
YoY Change		1300.0%	-100.0%
Total Long-Term Liabilities	$7.799M	$8.670M	$9.600M
YoY Change	-18.76%	86600.0%	95900.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.992M	$3.032M	$1.107M
Total Long-Term Liabilities	$7.799M	$8.670M	$9.600M
Total Liabilities	$10.98M	$11.70M	$10.71M
YoY Change	2.56%	948.39%	649.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$362.3M		-$349.1M
YoY Change	3.78%		4.15%
Common Stock	$367.4M		$367.0M
YoY Change	0.1%		1.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.052M	$7.580M	$17.92M
YoY Change
Total Liabilities & Shareholders Equity	$16.03M	$19.28M	$28.63M
YoY Change	-44.0%	-11.41%	-1.48%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q4
OPERATING ACTIVITIES
Net Income	-$2.696M	-$2.904M	-$3.417M
YoY Change	-21.1%	-8.97%	13.3%
Depreciation, Depletion And Amortization	$190.0K	$30.00K	$30.00K
YoY Change	533.33%	0.0%	0.0%
Cash From Operating Activities	-$2.350M	-$2.640M	-$3.160M
YoY Change	-25.63%	-15.38%	71.74%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	-$60.00K	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$1.910M	$400.0K	$3.180M
YoY Change	-39.94%	-81.04%	-115.91%
Cash From Investing Activities	$1.880M	$350.0K	$3.180M
YoY Change	-40.88%	-83.33%	-115.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	9.770M
YoY Change	-100.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-2.350M	-2.640M	-3.160M
Cash From Investing Activities	1.880M	350.0K	3.180M
Cash From Financing Activities	0.000	0.000	9.770M
Net Change In Cash	-470.0K	-2.290M	9.790M
YoY Change	-104.8%	-216.84%	-144.83%
FREE CASH FLOW
Cash From Operating Activities	-$2.350M	-$2.640M	-$3.160M
Capital Expenditures	-$30.00K	-$60.00K	$0.00
Free Cash Flow	-$2.320M	-$2.580M	-$3.160M
YoY Change	-26.58%	-17.31%	73.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2948000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48922	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47297	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48871	shares
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47458	shares
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48922	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47297	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48871	shares
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47458	shares
CY2014Q1	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	830000	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	829	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	25	shares
CY2014Q3	acur	Share Based Compensation Expense Recognized In Operations ShareBasedCompensationExpenseRecognizedInOperations	229000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0186	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.14	pure
CY2013Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	829	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	74	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47297	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5138	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48871	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47458	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48922	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4012	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.17
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2014Q3	acur	Restricted Stock Units Sale Price RestrictedStockUnitsSalePrice	0.01
	acur	Share Based Compensation Expense Recognized In Operations ShareBasedCompensationExpenseRecognizedInOperations	945000	USD
	acur	Share Based Compensation Expense Recognized In Operations ShareBasedCompensationExpenseRecognizedInOperations	716000	USD
CY2013Q3	acur	Share Based Compensation Expense Recognized In Operations ShareBasedCompensationExpenseRecognizedInOperations	315000	USD
CY2013	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	46800000	USD
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	137600000	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2013	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	2800000	USD
	acur	Weighted Average Number Of Shares Issued Basic And Diluted WeightedAverageNumberOfSharesIssuedBasicAndDiluted	46468	shares
	acur	Weighted Average Number Of Shares Issued Basic And Diluted WeightedAverageNumberOfSharesIssuedBasicAndDiluted	48846	shares
CY2013Q3	acur	Weighted Average Number Of Shares Issued Basic And Diluted WeightedAverageNumberOfSharesIssuedBasicAndDiluted	46629	shares
CY2014Q3	acur	Weighted Average Number Of Shares Issued Basic And Diluted WeightedAverageNumberOfSharesIssuedBasicAndDiluted	48848	shares
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	536000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	51000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	183000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-46000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	13000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-4000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-741000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-158000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	362000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1087000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	55000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	71000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-59000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10516000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8685000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	7611000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2203000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-62000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	10708000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2424000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	105000	USD
	us-gaap	Product Warranty Accrual Additions From Business Acquisition ProductWarrantyAccrualAdditionsFromBusinessAcquisition	0	USD
	us-gaap	Product Warranty Accrual Additions From Business Acquisition ProductWarrantyAccrualAdditionsFromBusinessAcquisition	2000000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	440000	USD
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5138	shares
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4012	shares
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	683000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3073000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1884000	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	945000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	716000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	93000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8000	USD
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	1000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	140000	USD
	acur	Amortization Of Bond Premium In Marketable Securities AmortizationOfBondPremiumInMarketableSecurities	0	USD
	acur	Amortization Of Bond Premium In Marketable Securities AmortizationOfBondPremiumInMarketableSecurities	201000	USD
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	1000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	716000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	529000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-1000	USD
	acur	Proceeds From Market Offering Of Shares ProceedsFromMarketOfferingOfShares	-3328000	USD
	acur	Proceeds From Market Offering Of Shares ProceedsFromMarketOfferingOfShares	0	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	104000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	90000	USD
	acur	Proceeds From Issuance Of Common Stock Value Under Market Offerings ProceedsFromIssuanceOfCommonStockValueUnderMarketOfferings	102000	USD
	acur	Proceeds From Issuance Of Common Stock Value Under Market Offerings ProceedsFromIssuanceOfCommonStockValueUnderMarketOfferings	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2520000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-43000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	353000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-520000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4923000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-11089000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7476000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2553000	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Interest Paid InterestPaid	557000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	42000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	acur	Provision To Reduce Inventory To Net Realizable Value ProvisionToReduceInventoryToNetRealizableValue	361000	USD
	acur	Provision To Reduce Inventory To Net Realizable Value ProvisionToReduceInventoryToNetRealizableValue	201000	USD
	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	-28000	USD
	dei	Entity Registrant Name EntityRegistrantName	ACURA PHARMACEUTICALS, INC
	dei	Entity Central Index Key EntityCentralIndexKey	0000786947
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Trading Symbol TradingSymbol	ACUR
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48847982	shares
CY2014Q3	acur	Longterm Portion Of Accrued Interest LongtermPortionOfAccruedInterest	140000	USD
CY2013Q4	acur	Longterm Portion Of Accrued Interest LongtermPortionOfAccruedInterest	0	USD
CY2014Q3	acur	Available For Sale Securities Debt Maturities After One Through Three Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue	4800000	USD
CY2013Q4	acur	Available For Sale Securities Debt Maturities After One Through Three Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue	5900000	USD
CY2014Q3	acur	Available For Sale Securities Debt Maturities After Three Through Four Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFourYearsFairValue	0	USD
CY2013Q4	acur	Available For Sale Securities Debt Maturities After Three Through Four Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterThreeThroughFourYearsFairValue	900000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	136000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	143000	USD
CY2013Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	55000	USD
CY2014Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	46000	USD
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-11000	USD
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-5000	USD
CY2013Q3	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-20000	USD
CY2014Q3	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	0	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	125000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-769000	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	35000	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-258000	USD
CY2013Q3	us-gaap	Revenues Revenues	83000	USD
CY2014Q3	us-gaap	Revenues Revenues	145000	USD
	acur	Cost Of Sales Excluding Inventory Write Down CostOfSalesExcludingInventoryWriteDown	78000	USD
	acur	Cost Of Sales Excluding Inventory Write Down CostOfSalesExcludingInventoryWriteDown	188000	USD
CY2013Q3	acur	Cost Of Sales Excluding Inventory Write Down CostOfSalesExcludingInventoryWriteDown	78000	USD
CY2014Q3	acur	Cost Of Sales Excluding Inventory Write Down CostOfSalesExcludingInventoryWriteDown	108000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	361000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	201000	USD
CY2013Q3	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2014Q3	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4120000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3674000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1289000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	955000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6138000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5903000	USD
CY2013Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1941000	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1728000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	9966000	USD
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	3308000	USD
CY2014Q3	us-gaap	Costs And Expenses CostsAndExpenses	2791000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9744000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3225000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2646000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1107000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3032000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	251000	USD
CY2014Q3	us-gaap	Inventory Net InventoryNet	403000	USD
CY2014Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	179000	USD
CY2013Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	231000	USD
CY2014Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2000000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	USD
CY2014Q3	us-gaap	Assets Assets	19280000	USD
CY2013Q4	us-gaap	Assets Assets	28630000	USD
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	116000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	274000	USD
CY2014Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1488000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	541000	USD
CY2014Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	40000	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5000	USD
CY2014Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	228000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	287000	USD
CY2014Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	1160000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2013Q4	us-gaap	Long Term Debt LongTermDebt	9600000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	10707000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	483000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	366533000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-349112000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	19000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	17923000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28630000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10484000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-10513000	USD
	acur	Percentage Of Royalty PercentageOfRoyalty	0.05	pure
	acur	Payment For Termination PaymentForTermination	2000000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	4000	USD
CY2014Q3	acur	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	200000	USD
CY2013Q4	acur	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	0	USD
CY2014Q3	acur	Prepaid Research And Development Expense Current PrepaidResearchAndDevelopmentExpenseCurrent	0	USD
CY2013Q4	acur	Prepaid Research And Development Expense Current PrepaidResearchAndDevelopmentExpenseCurrent	360000	USD
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48848	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48325	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48848	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48325	shares
CY2014Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	5000	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	28000	USD
CY2014Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	311000	USD
CY2013Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	400000	USD
CY2013	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	19000	USD
CY2014Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	3500000	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	3100000	USD
CY2013Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	13700000	USD
CY2014Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	13300000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	13700000	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	0	USD
	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	0	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	0	USD
	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	0	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	230000	USD
CY2014Q3	acur	Increase In Inventory Reserves IncreaseInInventoryReserves	450000	USD
CY2014Q3	us-gaap	Inventory Adjustments InventoryAdjustments	200000	USD
CY2014Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	260000	USD
CY2013Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	0	USD
CY2014Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	143000	USD
CY2013Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	501000	USD
CY2014Q3	us-gaap	Inventory Gross InventoryGross	403000	USD
CY2013Q4	us-gaap	Inventory Gross InventoryGross	501000	USD
CY2014Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	USD
CY2013Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	250000	USD
CY2014Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	339000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	78000	USD
CY2014Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	228000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	293000	USD
CY2014Q3	us-gaap	Interest Payable Current InterestPayableCurrent	69000	USD
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2014Q3	acur	Other Accrued Taxes Current OtherAccruedTaxesCurrent	9000	USD
CY2013Q4	acur	Other Accrued Taxes Current OtherAccruedTaxesCurrent	1000	USD
CY2014Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	17000	USD
CY2013Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	15000	USD
CY2014Q3	acur	Manufacturing Services Costs ManufacturingServicesCosts	0	USD
CY2013Q4	acur	Manufacturing Services Costs ManufacturingServicesCosts	14000	USD
CY2014Q3	acur	Accrued Other Professional Fees Current AccruedOtherProfessionalFeesCurrent	179000	USD
CY2013Q4	acur	Accrued Other Professional Fees Current AccruedOtherProfessionalFeesCurrent	0	USD
CY2014Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	647000	USD
CY2013Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	10000000	USD
CY2014Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0835	pure
CY2014Q3	acur	Debt Default Long Term Debt Percentage DebtDefaultLongTermDebtPercentage	0.1335	pure
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2018-12-01
	acur	Debt Instrument Deferment Of Amortization Date Description DebtInstrumentDefermentOfAmortizationDateDescription	The Amortization Date is April 1, 2015, but shall automatically become April 1, 2016 if we achieve 75% of our projected Nexafed cash receipts and 75% of our projected Aversion Oxycodone cash receipts for the fiscal year ending December 31, 2014 (collectively, the First Revenue Event).
	acur	Debt Instrument Further Deferment Of Amortization Date Description DebtInstrumentFurtherDefermentOfAmortizationDateDescription	The Amortization Date will be further deferred until April 1, 2017 if the First Revenue Event occurs and in addition we achieve 75% of our projected Nexafed cash receipts and 75% of our projected Aversion Oxycodone cash receipts for the fiscal year ending December 31, 2015 (collectively, the Second Revenue Event).
CY2014Q3	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	50000	USD
	acur	Debt Consulting Placement Fee DebtConsultingPlacementFee	100000	USD
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	231000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	767000	USD
CY2013Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2014Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	257000	USD
	acur	Interest Expense Debt Discount InterestExpenseDebtDiscount	0	USD
	acur	Interest Expense Debt Discount InterestExpenseDebtDiscount	89000	USD
CY2013Q3	acur	Interest Expense Debt Discount InterestExpenseDebtDiscount	0	USD
CY2014Q3	acur	Interest Expense Debt Discount InterestExpenseDebtDiscount	30000	USD
	us-gaap	Debt Issuance Costs DebtIssuanceCosts	0	USD
	us-gaap	Debt Issuance Costs DebtIssuanceCosts	51000	USD
CY2013Q3	us-gaap	Debt Issuance Costs DebtIssuanceCosts	0	USD
CY2014Q3	us-gaap	Debt Issuance Costs DebtIssuanceCosts	17000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	907000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	0	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	304000	USD
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1758000	USD
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2522000	USD
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2741000	USD
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	2979000	USD
CY2014Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	USD
CY2014Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	8000	USD
CY2013Q3	us-gaap	Royalty Revenue RoyaltyRevenue	3000	USD
CY2014Q3	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	80000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	218000	USD
CY2013Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	80000	USD
CY2014Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	145000	USD
	us-gaap	Revenues Revenues	88000	USD
	us-gaap	Revenues Revenues	222000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	140000	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3190000	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2904000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10484000	USD
	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	35000	USD
	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	6000	USD
CY2013Q3	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	114000	USD
CY2014Q3	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	-44000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	35000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	114000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-44000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10449000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10507000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3076000	USD

Files In Submission

Name	View Source	Status
0001144204-14-064695-index-headers.html	Edgar Link	pending
0001144204-14-064695-index.html	Edgar Link	pending
0001144204-14-064695.txt	Edgar Link	pending
0001144204-14-064695-xbrl.zip	Edgar Link	pending
acur-20140930.xml	Edgar Link	completed
acur-20140930.xsd	Edgar Link	pending
acur-20140930_cal.xml	Edgar Link	unprocessable
acur-20140930_def.xml	Edgar Link	unprocessable
acur-20140930_lab.xml	Edgar Link	unprocessable
acur-20140930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v391733_10q.htm	Edgar Link	pending
v391733_ex31-1.htm	Edgar Link	pending
v391733_ex31-2.htm	Edgar Link	pending
v391733_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACUR
ACURA PHARMACEUTICALS, INC Stock $acur

2014 Q4 Form 10-Q Financial Statement

#000114420414064695 Filed on November 03, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACUR ACURA PHARMACEUTICALS, INC Stock $acur

2014 Q4 Form 10-Q Financial Statement

#000114420414064695 Filed on November 03, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACUR
ACURA PHARMACEUTICALS, INC Stock $acur